Skip to main content
Clinical Trials/NCT02747914
NCT02747914
Suspended
Not Applicable

Repetitive Transcranial Magnetic Stimulation Boosted Exercise Therapy for Lower Limb Spasticity in Multiple Sclerosis Patients

University of Belgrade1 site in 1 country40 target enrollmentJanuary 25, 2021

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Multiple Sclerosis
Sponsor
University of Belgrade
Enrollment
40
Locations
1
Primary Endpoint
muscle tone measured by Modified Ashworth Scale (MAS)
Status
Suspended
Last Updated
last year

Overview

Brief Summary

Leg spasticity is common problem encountered with a large proportion of patients suffering with multiple sclerosis (MS) with an increasing severity as the disease progresses. It mostly affects the antigravity muscles that significantly complicates transfer, increases fatigue and makes walking more difficult. Hence, leg spasticity often interferes with patients' mobility and significantly influences their quality of life. A great number of multidisciplinary rehabilitation studies has shown a significant effect of numerous specific functional changes in patients with secondary (SP) and primary progressive (PP) MS but there are no reviews related to spasticity. The positive therapeutic effect of modulating Transcranial Magnetic Stimulation ( TMS) methods on spasticity is shown in only two studies, in patients with relapse remitting clinical form in the remission phase of the disease. The effect of TMS on clinical measures of lower limb spasticity, functional inability and the quality of life in patients with SPMS and PPMS will be examined in this study. The objective to this study are to to explore whether rTMS boosted exercise therapy (ET) treatment can bring more improvement in lower limb spasticity than ET treatment alone in these patients.

Registry
clinicaltrials.gov
Start Date
January 25, 2021
End Date
December 2025
Last Updated
last year
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Konstantinovic Ljubica

professor

University of Belgrade

Eligibility Criteria

Inclusion Criteria

  • Confirmed clinical form of SPMS and PPMS (established on the basis of the revised McDonald criteria)
  • EDDS score 2-6.5
  • lower limb spasticity caused by MS
  • 18 years ≥age of the patient ≤

Exclusion Criteria

  • clinical worsening of the disease over the past 30 days,
  • the presence of pregnancy, dementia, alcoholism, history of loss of consciousness, epilepsy, metal objects in the head, pacemakers and other electronic devices in the body at a distance of 20cm from the top of the patients head, serious associate diseases (malignancy, heart disease).

Outcomes

Primary Outcomes

muscle tone measured by Modified Ashworth Scale (MAS)

Time Frame: 3 weeks

Secondary Outcomes

  • impact of leg spasticity on daily activities measured by Multiple Sclerosis Spasticity Scale 88 (MSSS-88)(3 weeks)
  • Activities of daily living measured by Barthel Index(3 weeks)
  • Quality of life measured by Multiple Sclerosis Quality of Life 54 (MSQoL54).(3 weeks)
  • Walking mobility measured by Timed 25 Foot Walk test(3 weeks)

Study Sites (1)

Loading locations...

Similar Trials